NeuroPulse Wk 29: First Brain Link Shares Movement Between Two People
The Alzheimer’s Association International Conference drove the week’s pipeline news, but the signal that matters most came from a lab, not a podium: the first brain link that let one paralysed person move and feel through another. Around it, a tau target validated and contested in the same week, an oral entrant scaling in Huntington’s, and anti-amyloid therapy fighting its real battle, which is access, not efficacy.
readouts
actions
congress
first
Two paralysed people share touch and movement through a brain link, and the field crosses from restoring one body to networking two
The signal this week is not another incremental step in brain-computer interfaces, it is a category change. Feinstein Institutes researchers, publishing in Nature Medicine on 16 July, had one participant with paralysis use his cortical implant to move the hand of a second participant with a spinal cord injury, while feeling the sensations that second person’s fingertips registered. Read past the science-fiction framing and the commercial implication is concrete: BCI has been a single-patient restoration story, one implant, one nervous system, one closed loop. An interhuman loop reframes the addressable problem from motor prosthetics toward shared rehabilitation and networked neural systems, a far larger and largely unclaimed space. For anyone tracking the BCI competitive set, this is the kind of proof-of-concept that resets what the category is allowed to promise, and it came from an academic group rather than the venture-backed names that dominate the headlines.
Biogen advances diranersen to Phase 3 in early Alzheimer’s despite missing its primary endpoint
This is the readout to understand properly, because the headline (a failed primary) and the decision (advance to Phase 3) point in opposite directions, and the decision is the more informative one. Biogen’s anti-tau antisense oligonucleotide diranersen missed its Phase 2 CELIA primary of dose-dependent brain-tau reduction, and the stock took roughly an 8 percent hit. But all three doses beat placebo at 18 months, and the lowest 60mg arm slowed decline on CDR-SB by 26 percent with consistent tau reductions, the first Phase 2 evidence a drug can clear toxic tau tangles in Alzheimer’s. Biogen is betting the cognitive-and-biomarker signal matters more than the missed dose-response. The competitive read: this opens a tau lane alongside the approved amyloid antibodies rather than against them, and an inverse dose-response is a real derisking question Phase 3 will have to answer.
Skyhawk expands its pivotal FALCON-HD trial of SKY-0515 in Huntington’s to the US, Canada and UK
Skyhawk moved its Huntington’s program from a single-geography pivotal to a US, Canada and UK footprint for SKY-0515, an oral small-molecule RNA-splicing modulator. The mechanism is the story: an oral, brain-penetrant small molecule that lowers huntingtin by tuning splicing is a fundamentally different proposition from the intrathecal antisense approaches that have defined the space, on convenience and on cost of administration. Expanding a pivotal’s geography mid-stream signals internal confidence in enrollment and endpoints. In a disease where the highest-profile programs have stumbled, an oral entrant reaching multi-country pivotal scale is a competitive marker worth logging.
Voyager’s VY1706 clears GLP toxicology and heads for an Alzheimer’s trial in H2 2026
Voyager reported that a single IV dose of VY1706, a tau-lowering candidate, was well tolerated and reduced tau in a six-month GLP toxicology study, with first-in-human testing guided for H2 2026. This is early, and the honest read is that a clean tox package plus preclinical tau reduction is permission to start, not evidence of benefit. But it belongs on the board for two reasons: it adds another tau-lowering shot on goal in the same week Biogen validated the target clinically, and Voyager’s delivery platform is the differentiator to watch as these programs compete on getting into the brain efficiently.
Alkermes reports sustained wakefulness with oral alixorexton in narcolepsy long-term extension
Alkermes shared interim long-term extension data showing its oral orexin-2 agonist alixorexton sustained improvements in wakefulness across narcolepsy type 1 and type 2. Orexin agonism is one of the more contested competitive races in sleep-wake medicine right now, and durability in an extension study is exactly the evidence that separates a differentiated asset from an early flash. Type 2 coverage matters commercially, it widens the addressable population beyond the classic cataplexy-defined type 1. Mark this as a credible entrant in a field several large players are chasing simultaneously.
Longeveron’s laromestrocel cuts neuroinflammation in Alzheimer’s at AAIC
Longeveron presented data indicating its cellular therapy laromestrocel reduced neuroinflammation in Alzheimer’s patients. A cell therapy targeting neuroinflammation sits well outside the amyloid-and-tau mainstream, which is precisely why it is worth tracking: if the field’s center of gravity keeps shifting toward inflammation as a driver rather than a bystander, differentiated mechanisms gain option value. Early data, small numbers, but a genuinely distinct approach in a disease where the dominant hypotheses have delivered modest clinical returns.
Axsome’s AXS-12 accepted by FDA for cataplexy in narcolepsy
The FDA accepted Axsome’s NDA for AXS-12 (reboxetine) in cataplexy, moving it to a review decision. Acceptance is the procedural milestone, but the strategic point is portfolio: Axsome is assembling a CNS franchise, and a cataplexy approval would slot alongside its existing depression and migraine assets to build commercial density in neuropsychiatry. In narcolepsy specifically, note the crowding, this lands in the same brief as Alkermes’ orexin data, and competitive intensity in sleep-wake disorders is rising on both the wakefulness and cataplexy axes.
FDA approves Leqembi IQLIK, a subcutaneous initiation dose for early Alzheimer’s
Eisai secured approval for a subcutaneous autoinjector initiation dose of lecanemab (Leqembi IQLIK), with supporting data showing efficacy and safety comparable to the IV formulation. This is an access and convenience move more than a clinical one, and that is the point: the barrier to anti-amyloid uptake has never been only efficacy, it is the infrastructure burden of IV infusion. A subcutaneous option changes where and how easily patients can be treated, which is the real-world lever on a therapy whose commercial performance has been gated by administration friction, not just label. The reimbursed-population question follows the convenience question here.
Universal Brain wins FDA 510(k) for a rapid brain-function platform in psychiatry
Universal Brain received 510(k) clearance for a rapid brain-function measurement platform aimed at psychiatry. Objective, fast measurement in a field still largely dependent on clinical scales is a structural gap, and a cleared device that starts to fill it has a clear commercial logic in trial enrichment and, eventually, clinical triage. Clearance is the entry ticket; adoption will hinge on whether the readout changes a decision clinicians currently make on judgment alone.
Imperative Care launches the Ikon 24 Pro guidewire to speed its Zoom stroke system
Imperative Care launched the Ikon 24 Pro guidewire as an enhancement to its Zoom stroke thrombectomy system. Incremental on its face, but stroke intervention is a workflow-and-time business, every minute saved in a procedure maps to outcomes, and a device maker building out a complete, faster stroke-procedure stack is competing on integration, not just the individual tool. Log it as a portfolio-deepening move in the neurovascular device race rather than a standalone launch.
Sound Pharma completes enrollment in a Phase 3 study of SPI-1005 in Meniere’s disease
Sound Pharma fully enrolled its open-label Phase 3 of SPI-1005 in Meniere’s disease, a condition with limited disease-modifying options and real unmet need. Completing a Phase 3 enrollment in an under-served otologic indication is a quiet but real signal, these are exactly the neglected neuro-adjacent spaces where a first credible entrant can define the category. The open-label design tempers how much the eventual data will settle, but reaching full Phase 3 enrollment is a genuine progress marker.
NeuraLight’s brain-function measurement wins a Fast Company World Changing Ideas award
NeuraLight was recognised by Fast Company for its oculometric brain-function measurement technology. Awards are not evidence, and this belongs on the board with that caveat stated plainly. What it flags is momentum in a real thesis: extracting objective neurological readouts from the eye, cheaply and non-invasively, is a plausible route to scalable neuro assessment. Worth watching whether the validation data follows the recognition.
Servier completes its acquisition of Edgewise’s muscular dystrophy business
Servier closed its purchase of Edgewise Therapeutics’ muscular dystrophy assets, taking ownership of a neuromuscular pipeline. The read for a deal watcher is directional: Servier is buying committed, later-shaped neuromuscular programs rather than betting on discovery, which is the pattern of a company building depth in a defined therapeutic lane. Muscular dystrophy sits at the neuro-rare intersection, so this also reads as a bet on the rare-disease economics that keep drawing acquirers, durable orphan pricing against defined, motivated patient populations.
Ionis doses the first participant in the Phase 1/2 ASCEND study of ION337 in Dravet syndrome
Ionis began dosing in a Phase 1/2 study of ION337, an antisense candidate, in Dravet syndrome, a severe genetic pediatric epilepsy. This is early-stage, and the honest framing is first-shot-on-goal rather than proof. But it earns its place: Dravet is a defined genetic epilepsy with intense advocacy and clear unmet need, and antisense is the modality that already transformed spinal muscular atrophy. A first-in-human start from the acknowledged leader in the chemistry is a meaningful entry to log, and it is the kind of rare-pediatric story that travels.
When a development gets big enough, it earns a full report in The Pipeline.
Synopulse’s monthly intelligence line: deep, single-subject reports on the moves that reshape a field.